首页> 外文期刊>Bone >Contribution of the intra-specimen variations in tissue mineralization to PTH- and raloxifene-induced changes in stiffness of rat vertebrae.
【24h】

Contribution of the intra-specimen variations in tissue mineralization to PTH- and raloxifene-induced changes in stiffness of rat vertebrae.

机译:样本内组织矿化变化对PTH和雷洛昔芬诱导的大鼠椎骨硬度变化的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

The intra-specimen spatial variation in mineralization of bone tissue can be changed by drug treatments that alter bone remodeling. However, the contribution of such changes to the overall biomechanical effect of a treatment on bone strength is not known. To provide insight into this issue, we used a rat model to determine the effects of ovariectomy, parathyroid hormone, and raloxifene (vs. sham) on the contribution of spatial variations in mineralization to treatment-induced changes in vertebral stiffness. Mineral density was measured from 6-microm voxel-sized quantitative micro-CT scans. Whole-vertebral and trabecular stiffness values were estimated using finite element analysis of these micro-CT scans, first including all intra-specimen variations in mineral density in the model and then excluding such variations by using a specimen-specific average density throughout each specimen. As expected, we found appreciable effects of treatment on overall bone stiffness, the effect being greater for the trabecular compartment (up to 52% reduction vs. sham, p<0.0001) than the whole vertebra (p=0.055). Intra-specimen mean mineralization was not changed with treatment but the intra-specimen variation in mineralization was, although the effect was small (4%). Intra-specimen spatial variations in mineralization accounted for 10-12% and 5-6% of overall stiffness of the trabecular compartment and whole vertebral body, respectively. However, after accounting for all treatment effects on bone geometry and trabecular microstructure, any treatment effects due to changes in mineralization were negligible (<2%), although statistically detectable (p<0.02). We conclude that, despite a role in the general biomechanical behavior of bone, the spatial variations in tissue mineralization, as measured by quantitative micro-CT, did not appreciably contribute to ovariectomy-, PTH-, or raloxifene-induced changes in stiffness of the whole bone or the trabecular compartment in these rat vertebrae.
机译:可以通过改变骨重塑的药物治疗来改变骨组织矿化的标本内部空间变化。然而,这种改变对治疗对骨强度的整体生物力学作用的贡献尚不清楚。为了提供对该问题的见解,我们使用了大鼠模型来确定卵巢切除术,甲状旁腺激素和雷洛昔芬(对假手术)对矿化空间变化对治疗引起的椎体硬度变化的影响。矿物质密度是通过6微米体素大小的定量微CT扫描测量的。使用这些微型CT扫描的有限元分析来估算整个椎骨和小梁的刚度值,首先包括模型中所有样本内矿物质密度的变化,然后通过使用每个样本的样本特定平均密度来排除这种变化。正如预期的那样,我们发现治疗对总体骨硬度的影响明显,小梁腔的效果(与假手术相比降低了52%,p <0.0001)比整个椎骨大(p = 0.055)。尽管影响很小(4%),但标本内平均矿化度并未随处理而改变,但标本内矿化度却发生了变化。标本内矿化的空间变化分别占小梁区室和整个椎体整体刚度的10-12%和5-6%。但是,在考虑了所有对骨几何形状和小梁微结构的治疗效果后,尽管可以统计学检测到(p <0.02),但由于矿化变化引起的任何治疗效果均可以忽略不计(<2%)。我们得出的结论是,尽管在骨骼的一般生物力学行为中起作用,但通过定量显微CT测量的组织矿化的空间变化并没有明显促进卵巢切除术,PTH或雷洛昔芬引起的骨骼硬度变化。这些大鼠椎骨中的整个骨骼或小梁腔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号